If you have been reading about LC-MS/MS and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Updated 2026-02-08. Numbers and descriptions here follow the published literature rather than marketing material.
AOD-9604 is a synthetic peptide whose sequence matches the C-terminal fragment of human growth hormone, specifically residues 176 through 191. This region differs from the full hormone in its receptor interactions. The peptide is not a growth hormone secretagogue and does not bind the growth hormone receptor in the same manner. Researchers have examined it for effects on lipid metabolism, but its exact pharmacological profile remains an active area of study.
Development of AOD-9604 began in the 1990s as scientists sought to isolate metabolic effects of growth hormone without its growth-promoting actions. Early laboratory work focused on fat cells and animal models. Several human trials followed, examining changes in body composition and fat mass. Results have been mixed, and the peptide has not progressed to widespread clinical approval. Interest continues in research settings, particularly regarding its mechanism and potential metabolic targets.
Regulatory status varies by country. In the United States, AOD-9604 is not approved as a prescription drug. It is sometimes sold as a research chemical or dietary supplement, though such marketing may fall outside legal frameworks. The World Anti-Doping Agency prohibits its use in sport. Researchers must obtain it through legitimate suppliers and follow institutional rules. Its legal classification continues to evolve as authorities increasingly assess peptide products more broadly.
Clinical development of AOD-9604 included trials in people with obesity. Reports from early-phase and mid-phase studies described modest or inconsistent changes in body weight. A phase IIb program did not meet its primary endpoint, and the compound was not approved for medical use. Differences in formulation, delivery route, and participant characteristics may explain some of the variation. Later investigations explored whether the peptide might have effects in other tissues, including cartilage.
Regulatory treatment of AOD-9604 is shaped by its classification as a peptide hormone. The World Anti-Doping Agency lists it as a prohibited substance, and many national anti-doping organizations adopt that list. It does not hold approval as a prescription medicine in the United States, the European Union, or other major markets. Products sold online are frequently labeled for research use only and may not undergo independent quality testing. Import and possession rules differ by country, so legal status depends on local law.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Peptide fragment | Corresponds to hGH residues 176-191 |
| Common synonyms | AOD9604, hGH 176-191 | Also written as AOD-9604 |
| Typical form | Lyophilized powder | Often supplied in sealed vials |
| Solubility | Water-soluble | Dissolves in aqueous buffers |
| Regulatory status | Not approved as drug | Banned in sport; varies by country |
AOD9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It corresponds to a short sequence near the end of the 191-amino-acid hormone, often described as residues 176–191 or a related fragment. Researchers designed it to separate metabolic effects from the growth-promoting actions of full-length growth hormone. Early work in the 1990s explored it as a candidate for weight and lipid disorders. It is not a naturally circulating hormone fragment produced in large amounts.
Laboratory studies have reported that AOD9604 can increase lipolysis and reduce lipid accumulation in fat cells. The precise molecular target remains uncertain, and the compound does not appear to activate the growth hormone receptor in the same way as full-length hGH. Proposed mechanisms include effects on beta-adrenergic signaling and enzymes involved in fatty acid synthesis, but these pathways are not firmly established. Because most evidence comes from cell and animal models, whether the same effects occur in humans is an open question.
Clinical development of AOD9604 included trials in people with obesity, but the results did not lead to approval as a prescription medicine in major markets. Interest later shifted to research settings and to unapproved products marketed for body composition. Regulatory agencies have questioned whether the peptide qualifies as a dietary ingredient, and some have issued warnings about its presence in supplements. Long-term human safety data are limited, and questions about efficacy, dosing, and target populations remain unresolved.
AOD-9604 is listed as a prohibited substance in sport by the World Anti-Doping Agency. It falls under the peptide hormones, growth factors, related substances, and mimetics class on the prohibited list. Anti-doping organizations treat its presence in an athlete's sample as an adverse finding unless a therapeutic use exemption applies. The prohibition reflects concerns about performance enhancement in competitive settings and the difficulty of distinguishing exogenous peptide use from endogenous hormone fragments.
Detection of AOD-9604 in biological samples relies on analytical techniques capable of distinguishing a small synthetic peptide from related endogenous sequences. Liquid chromatography coupled with tandem mass spectrometry is commonly used for confirmatory analysis. Sample preparation may involve immunoaffinity enrichment or solid-phase extraction to concentrate the peptide. Because the molecule is small and may be present at low concentrations, assay sensitivity and specificity are ongoing analytical challenges. Laboratories also validate methods against reference materials when available.
Regulatory interest in AOD-9604 increased after high-profile anti-doping cases involving peptide products. In some cases, the substance was supplied under alternative names or in compounded preparations, complicating traceability. Sports tribunals and anti-doping panels have discussed whether the peptide was explicitly banned at the time of use, leading to clarifications by the World Anti-Doping Agency. For consumers and researchers, the legal status can vary by jurisdiction, and products marketed as research chemicals may lack independent quality verification.
The compound has been studied as a potential treatment for obesity and related metabolic conditions. Published trials have examined changes in body weight, fat mass, and safety markers over limited durations. Results have been mixed or modest, and no large-scale outcome trials are established. Regulatory agencies in several countries have not approved it as a therapeutic drug. Some commercial products have been marketed outside regulated pharmaceutical channels, which raises questions about quality and claims.
In the scientific literature, AOD-9604 appears in reviews of growth hormone fragments and in discussions of peptide-based metabolic research. Some sources distinguish it from growth hormone itself, while others group it with compounds marketed for weight management. The evidence base is small compared with approved obesity medications. Questions about long-term efficacy and clinical relevance remain open, and independent replication of key findings is limited. Most published reports are early-stage and exploratory.
Breakthrough T1D (formerly JDRF) is a type 1 diabetes (T1D) research and advocacy organization. Breakthrough T1D funds research for the development of new therapies and treatments for type 1 diabetes. The organization advocates for federal research funding toward new technologies and treatments and works with regulatory and policy officials to disburse funds. Breakthrough T1D also has partnerships with academia, industry, and clinicians to accelerate research into potential cures for T1D. The organization has been described as "the leading global organization funding T1D research".
== Clinical significance == Parenteral (intravenous) administration of glucagon is a common human medical intervention in diabetic emergencies when sugar cannot be given orally. It can also be administered intramuscularly.
== Epidemiology == A 1994 community-based study indicated that two out of every 100,000 people with a sCSF, while a 2004 emergency room-based study indicated five per 100,000. sCSF leaks generally affect the young and middle aged; the average age for onset is 42.3 years, but onset can range from ages 22 to 61. In an 11-year study, women were found to be twice as likely to be affected as men. Studies have shown that sCSF leaks runs in families. It is suspected that genetic similarity in families includes weakness in the dura mater which leads to a sCSFL. Large scale population-based studies have not yet been conducted. While a majority of sCSF leaks continue to be undiagnosed or misdiagnosed, an actual increase in occurrence is unlikely.
Daly, M.M.; Mirsky, A.E. (January 1955). "Histones With High Lysine Content". Journal of General Physiology. 38 (3): 405–413. doi:10.1085/jgp.38.3.405. PMC 2147486. PMID 13221780. Allfrey, V.G.; Daly, M.M.; Mirsky, A.E. (January 20, 1955). "Some Observations on Protein Metabolism in Chromosomes of Non-Dividing Cells" (PDF). Journal of General Physiology. 38 (3): 415–424. doi:10.1085/jgp.38.3.415. PMC 2147482. PMID 13221781. Daly, M.M.; Allfrey, V.G.; Mirsky, A.E. (November 20, 1955). "Synthesis of Protein in the Pancreas. III. Uptake of Glycine-N15 by the Trypsinogen and Chymotrypsinogen of Mouse Pancreas" (PDF). Journal of General Physiology. 39 (2): 207–210. doi:10.1085/jgp.39.2.207. PMC 2147525. PMID 13271721. Deming, Q.B.; Mosbach, E.H.; Bevans, M.; Daly, M.M.; Abell, L.L.; Martin, E.; Brun, L.M.; Halpern, E.; Kaplan, R. (April 1, 1958). "Blood Pressure, Cholesterol Content of Serum and Tissues and Atherogenesis in the Rat" (PDF). The Journal of Experimental Medicine. 107 (4): 581–598. doi:10.1084/jem.107.4.581. PMC 2136835. PMID 13513919. Daly, Marie M.; Gupride, E. Gambetta (February 1, 1959). "The Respiration and Cytochrome Oxidase Activity of Rat Aorta in Experimental Hypertension" (PDF). Journal of Experimental Medicine. 109 (2): 187–195. doi:10.1084/jem.109.2.187. PMC 2136939. PMID 13620848. Adel, Harold; Daly, Marie M.; Deming, Quentin B.; Brun, Lili; Raeff, Victoria (1962). "Effect of Hypertension on Cholesterol Synthesis in Rats" (PDF).
Sources: en.wikipedia.org
When the fetus is exposed to testosterone, the genital tubercle elongates (primordial phallus) and develops into the glans and shaft of the penis and the urogenital folds fuse to become the penile raphe. The urethra within the penis (except within the glans) is developed from the urogenital sinus.
An independent panel upholds the Parliamentary Commissioner for Standards' decision that Scott Benton, MP for Blackpool South, should face a 35-day suspension from Parliament. The suspension will now be voted on by MPs and could trigger another by-election. Heather Woodbridge, aged 29, is appointed as leader of Orkney Islands Council, becoming Scotland's youngest council leader and the first woman to lead Orkney Islands Council. 21 February – An Opposition day House of Commons debate calling for a ceasefire in Gaza descends into chaos after Speaker Sir Lindsay Hoyle breaks with Parliamentary convention to allow a vote on a Labour amendment calling for an "immediate humanitarian ceasefire" over the scheduled SNP motion calling for an "immediate ceasefire". The decision leads to protests from both Conservative and SNP MPs, who walk out of the House, leaving Labour's motion to be nodded through when the other two parties do not take part in the vote. Amid calls for his resignation, Hoyle says that he allowed the House to vote on the Labour motion so MPs could express their view on "the widest range of propositions", and to protect MPs' safety. King Charles III is seen back at work and meeting Prime Minister Rishi Sunak, the first time he has been seen back at work since his cancer diagnosis. Senior civil servant Sarah Munby writes to the Business Secretary to reject allegations by former Post Office chairman Henry Staunton that he was told to delay compensation payments to victims of the Horizon scandal.
PGA is used for stabilizing the δ phase of plutonium, avoiding the α-phase and α–δ related issues. Its main use is in pits of implosion bombs. Plutonium–aluminium is an alternative to PGA. It was the original element considered for δ phase stabilization, but its tendency to react with the alpha particles and release neutrons reduces its usability for nuclear weapons. Plutonium–aluminium alloy can be also used as a component of nuclear fuel. Plutonium–gallium–cobalt alloy (PuCoGa5) is an unconventional superconductor, showing superconductivity below 18.5 K, an order of magnitude higher than the highest between heavy fermion systems, and has large critical current. Plutonium–zirconium alloy can be used as nuclear fuel. Plutonium–cerium and plutonium–cerium–cobalt alloys are used as nuclear fuels. Plutonium–uranium, with about 15–30 mol.% plutonium, can be used as a nuclear fuel for fast breeder reactors. Its pyrophoric nature and high susceptibility to corrosion to the point of self-igniting or disintegrating after exposure to air require alloying with other components. Addition of aluminium, carbon or copper does not improve disintegration rates markedly, zirconium and iron alloys have better corrosion resistance but they disintegrate in several months in air as well. Addition of titanium and/or zirconium significantly increases the melting point of the alloy. Plutonium–uranium–titanium and plutonium–uranium–zirconium were investigated for use as nuclear fuels.
Sources: en.wikipedia.org
Nitrogen dioxide poisoning is the illness resulting from the toxic effect of nitrogen dioxide (NO2). It usually occurs after the inhalation of the gas beyond the threshold limit value. Nitrogen dioxide is reddish-brown with a very harsh smell at high concentrations, at lower concentrations it is colorless but may still have a harsh odour. Nitrogen dioxide poisoning depends on the duration, frequency, and intensity of exposure. Nitrogen dioxide is an irritant of the mucous membrane linked with another air pollutant that causes pulmonary diseases such as obstructive lung disease, asthma, chronic obstructive pulmonary disease and sometimes acute exacerbation of COPD and in some cases, death. Its poor solubility in water enhances its passage and its ability to pass through the moist oral mucosa of the respiratory tract. Like most toxic gases, the dose inhaled determines the toxicity on the respiratory tract. Occupational exposures constitute the highest risk of toxicity and domestic exposure is uncommon. Prolonged exposure to low concentration of the gas may have lethal effects, as can short-term exposure to high concentrations like chlorine gas poisoning. It is one of the major air pollutants capable of causing severe health hazards such as coronary artery disease as well as stroke. Nitrogen dioxide is often released into the environment as a byproduct of fuel combustion but rarely released by spontaneous combustion. Known sources of nitrogen dioxide gas poisoning include automobile exhaust and power stations.
With a worldwide box-office gross of over $2.9 billion, Avatar is proclaimed to be the "highest-grossing" film, but such claims usually refer to theatrical revenues only and do not take into account home video and television income, which can form a significant portion of a film's earnings. Once revenue from home entertainment is factored in, it is not immediately clear which film is the most successful. Titanic earned $1.2 billion from video and DVD sales and rentals, in addition to the $2.2 billion it grossed in theaters. While complete sales data are not available for Avatar, it earned $345 million from the sale of sixteen million DVD and Blu-ray units in North America, and ultimately sold a total of thirty million DVD and Blu-ray units worldwide. After home video income is accounted for, both films have earned over $3 billion each. Television broadcast rights also substantially add to a film's earnings and, as of 2010, a film often earned the equivalent of as much as 20–25% of its theatrical box office for two television runs, on top of pay-per-view revenues; Titanic earned a further $55 million from the NBC and HBO broadcast rights, equating to about 9% of its North American gross. When a film is highly exploitable as a commercial property, its ancillary revenues can dwarf its income from direct film sales. The Lion King (1994) earned over $2 billion in box-office and home video sales, but this pales in comparison to the $8 billion earned at box offices around the world by the stage adaptation.
=== Thermochemistry === L. K. Doraiswamy, 2005, "Estimation of properties of organic compounds (Ch. 3)," pp. 36–51, 118-124 (refs.), in Organic Synthesis Engineering, Oxford, Oxon, ENG:Oxford University Press, ISBN 0198025696, accessed 22 June 2015. (This book chapter surveys a very wide range of physical properties and their estimation, including the narrow list of thermochemical properties appearing in the June 2015 WP article, placing the Benson et al. method alongside many other methods. L. K. Doraiswamy is Anson Marston Distinguished Professor of Engineering at Iowa State University.) Irikura, Karl K.; Frurip, David J. (1998). "Computational Thermochemistry". In Irikura, Karl K.; Frurip, David J. (eds.). Computational Thermochemistry: Prediction and Estimation of Molecular Thermodynamics. ACS Symposium Series. Vol. 677. American Chemical Society. pp. 2–18. doi:10.1021/bk-1998-0677.ch001. ISBN 978-0-8412-3533-5.
Sources: en.wikipedia.org
AOD-9604 is a synthetic peptide fragment of human growth hormone, corresponding to amino acids 176-191. It is studied for potential effects on fat metabolism, but it is not approved as a drug in most countries. Its exact mechanism remains under investigation.
No, it is a small fragment of the full growth hormone protein. It does not appear to stimulate growth or increase growth hormone levels in the same way. Its actions are thought to be more limited to metabolic pathways.
Regulatory status varies. It is not approved for medical use in the United States or many other countries. It is banned in sport by WADA, and its sale as a supplement or research chemical may be subject to legal restrictions.
No. Major drug regulators have not approved AOD-9604 for weight loss or any other therapeutic indication. It remains an investigational compound studied in research settings.